Levodopa/carbidopa subcutaneous - NeuroDerm

Drug Profile

Levodopa/carbidopa subcutaneous - NeuroDerm

Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroDerm
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 21 May 2018 NeuroDerm initiates enrolment in a phase III trial for Parkinson's disease (Adjunctive treatment) in Spain (SC) (EudraCT2017-002780-17)
  • 12 Mar 2018 NeuroDerm plans a pivotal phase III trial for Parkinson's disease (Late-stage disease, Treatement-experienced) in Italy (NCT03462043)
  • 18 Oct 2017 NeuroDerm has been acquired by Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top